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Background. The correct management of immunocompromised patients with pneumonia is debated. We evaluated the preva-
lence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia.
Methods. We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the 
community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise 
included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplanta-
tion, chronic steroid use, and solid tumor.
Results. At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk 
factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemo-
therapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the 
most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompro-
mise were independently associated with neither Pseudomonas aeruginosa nor non–community-acquired bacteria. Specific risk factors 
were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both 
P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001).
Conclusions. Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immuno-
compromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, 
mycobacteria, and noninfluenza viruses.
Keywords. pneumonia; multidrug-resistant pathogens; microbiology; MRSA; immunocompromise.
During initial evaluation of a patient coming from the commu-
nity with pneumonia, the identification of possible risk factors 
for multidrug-resistant organisms or unusual pathogens is cru-
cial [1–3]. Because a microbiological identification is found in 
about 30% of hospitalized patients with pneumonia coming 
from the community, and usually requires 24–48 hours to be 
available, most of patients are treated empirically [4]. Delay in 
initiation of appropriate empiric antibiotic therapy is a known 
risk factor for worse clinical outcomes [5–7]; therefore, it is rel-
evant to promptly recognize patients at risk for specific patho-
gens, specially multidrug-resistant or atypical microbes [1–3].
The aging of the population and advancements in therapeutic 
protocols have led to an increase prevalence of chronic diseases 
as well as long-term treatments with immunosuppressive agents 
[8, 9]. Thus, among patients with pneumonia coming from the 
community and admitted to the hospital, the number who 
might not be fully immunocompetent is constantly increasing 
[8, 9]. Nevertheless, the real prevalence of immunocompromise 
among patients with pneumonia coming from the community 
is still unknown. Moreover, guidelines for community-acquired 
and hospital-acquired pneumonia did not address this topic—
what is more, they specifically excluded patients with clinical 
characteristics determining immunocompromise [5–7], and 
current evidence in literature is also scarce.
To our knowledge, there are no studies addressing the clinical 
evaluation and initial empirical antibiotic coverage of patients 
coming from the community with pneumonia and immuno-
compromise. Moreover, specific risk factors to assess the causa-
tive microbiology and help clinicians choose more appropriate 
management for these patients have not been clearly identified. 
Thus, the aim of the current study was to identify the prevalence, 
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type, microbiology, and intercorrelations between different risk 
factors for immunocompromise in hospitalized patients with 
pneumonia coming from the community.
MATERIALS AND METHODS
Study Design and Population
This is a secondary analysis of the Global Initiative for MRSA 
Pneumonia (GLIMP) database [10]. The GLIMP study was 
an international, multicenter, observational, point-prevalence 
study of adult patients hospitalized for community-onset pneu-
monia in 54 countries worldwide. Patients were enrolled on a 
single day during the months of March, April, May, and June 
2015. The methods of the GLIMP study have been published 
elsewhere [10]. The coordinating center (University of Texas 
Health Science Center, San Antonio) received approval from its 
institutional review board (No. HSC20150184E).
All adult patients (aged >18 years old) coming from the com-
munity and hospitalized with pneumonia during study period 
were included. Pneumonia was defined as the presence of a new 
pulmonary infiltrate on chest radiograph at the time of hospi-
talization, associated with ≥1 of the following criteria: (1) new 
or increased cough with/without sputum production and/or 
purulent respiratory secretions, (2) fever or hypothermia, and 
(3) evidence of systemic inflammation (ie, abnormal white 
blood cell count or increased C-reactive protein or procalci-
tonin level). Hospitalized patients with a diagnosis of hospi-
tal-acquired or ventilator-associated pneumonia were excluded.
Data Collection
Data were collected from medical records at the time of hospital 
admission. Data gathered included demographics; respiratory 
and cardiovascular comorbid conditions; immunocompro-
mised status and other chronic medical conditions; severity of 
pneumonia (defined as either intensive care unit admission, 
use of invasive or noninvasive mechanical ventilation, or use 
of vasopressors/inotropes during the first 24 hours after hospi-
tal admission); and specific risk factors for resistant pathogens 
infection, including chronic aspiration, being bedridden, mal-
nutrition, presence of enteric tube feeding and indwelling cath-
eters (including central venous and urinary catheters), previous 
infections, chronic microbial colonization, and previous health-
care exposures. The number and type of microbiological sam-
ples obtained within 24 hours after hospital admission were also 
collected. Culture-positive tests, kind of sample, and antibiotic 
resistance patterns were also gathered, along with empiric anti-
biotic treatment, given within 24 hours after hospital admission.
Microbiological Workup
Diagnostic testing was performed according to local standard 
operating procedures and included collection of respiratory and 
blood cultures and testing for urinary antigens. Microbiological 
examinations and susceptibility testing were performed 
according to local standard protocols within the first 24 hours 
after hospital admission [11]. Multivariable logistic regression 
models were performed for patients who had a positive culture, 
to identify specific risk factors for single pathogens.
Causative pathogens were stratified according to the cov-
erage of standard therapy for community-acquired pneu-
monia (CAP) [5–7]. Those not covered by standard CAP 
therapy included the following: non–community-acquired 
bacteria (Acinetobacter baumanii, Enterococcus vancomy-
cin-resistant, Nocardia spp.), mycobacteria, fungi (Aspergillus 
fumigatus, Coccidioides, Criptococcus, Pneumocystis jirovecii), 
and viruses other than influenza [5–7]. Those covered by stan-
dard CAP therapy included Pseudomonas aeruginosa, meth-
icillin-resistant Staphylococcus aureus, methicillin-sensitive 
S. aureus, Enterobacter spp., Enterococcus spp., Escherichia coli, 
Haemophilus influenzae, Klebsiella pneumoniae, Moraxella 
catarrhalis, Proteus mirabilis, Serratia marcescens, Streptococcus 
pneumoniae, Chlamydia pneumoniae, Mycoplasma pneu-
moniae, Legionella pneumophilia, anaerobes bacteria, and 
influenza viruses. Atypical pathogens included C.  pneumo-
niae, M.  pneumoniae, and L.  pneumophilia. CAP therapy was 
defined as β-lactams (ceftriaxone, ampicillin-sulbactam, amox-
icillin-clavulanate, cefepime, ceftazidime, piperacillin-tazobac-
tam) plus macrolide, or fluoroquinolones alone, and, eventually, 
in association with vancomycin, linezolid, or oseltamivir [5–7].
Definition of Immunocompromised and Study Groups
Immunocompromise was defined as the presence of ≥1 of the 
following risk factors: (1) AIDS, defined either as human immu-
nodeficiency virus infection with CD4+ lymphocyte count 
<200/µL or by the occurrence of AIDS-defining conditions; (2) 
aplastic anemia; (3) asplenia; (4) hematological cancer, defined 
as lymphoma, acute or chronic leukemia, or multiple myeloma; 
(5) chemotherapy during the last 3  months; (6) neutropenia, 
defined as a neutrophil count <500/dL at complete blood cell 
count; (7) biological drug use (including trastuzumab and ther-
apies for autoimmune diseases, eg, anti–tumor necrosis factor 
α, prescribed during ≥6 months before hospital admission); (8) 
lung transplantation; (9) chronic steroid use (>10 mg/d of pred-
nisone or equivalent ≥3  months before hospital admission); 
(10) lung cancer with either neutropenia or chemotherapy; 
(11) other solid tumor with either neutropenia or chemother-
apy; (12) other immunocompromise (any immunocompro-
mised state, including congenital/genetic immunocompromise 
and immunosuppressive therapy due to hematological cancer/
solid organ transplantation other than lung). Two study groups 
were identified: those with versus those without 1 risk factor for 
immunocompromise.
Statistical Analysis
Categorical variables, expressed as counts (percentages), were 
compared using the χ2 test. Continuous variables were com-
pared using the unpaired Student t test or the Mann-Whitney 
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test, when appropriate. Statistical significance was defined as 
P  <  .05. A  network analysis was conducted to represent the 
frequencies of all immunocompromise variables and their rela-
tionships. The size of the circles (the circles visible in Figure 
4 [network analysis], each representing a single risk factor for 
immunocompromise) represents both prevalence of the risk 
factor and strength of association with other variables.
The predictive value of each variable was categorized by quar-
tiles and analyzed using a univariate regression logistic analysis. 
A  multivariable model was obtained using a Cox regression 
analysis to identify independent predictors of specific patho-
gens, using an entry level of P value ≤0.05 and a removal level 
of P value ≥0.10. Hazard ratios and adjusted analyses were 
obtained. All statistical analyses were performed with IBM 
SPSS software (version 22, Statistics for Mac; version 22.0, IBM 
Crop), and Stata 13 software (StataCorp).
RESULTS
Prevalence of Risk Factors for Immunocompromise
Among 3702 patients enrolled in the GLIMP database, ≥1 risk 
factor for immunocompromise was identified in 652 (17.6%). 
The prevalences of patients with pneumonia coming from the 
community and with ≥1 risk factor for immunocompromise 
differed among continents and countries, as depicted in Figure 1 
and Supplementary Tables 1 and 2. The prevalence of immuno-
compromise was significantly higher in both North and South 
America than in the rest of the world (24.0% vs 16.5 [P < .001] and 
24.8% vs 17.2 [P = .006], respectively) (Supplementary Table 1).
Figure 1. Distribution of prevalence of immunocompromise among the different countries participating in the study, categorized as no data, <5%, 5%–10%, 11%–20%, 
21%–30%, or >30% of total cases.
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The prevalence of each risk factor for immunocompromise 
is depicted in Figure 2, with chronic steroid use (45.0%), hema-
tological cancer (25.0%), and chemotherapy (22.0%) being the 
most frequent ones. A total of 312 patients (8.4%) had >1 risk 
factor for immunocompromise (Figure 3).
Network Analysis Among Risk Factors for Immunocompromise
The results of the network analysis of all risk factors for immu-
nocompromise are depicted in Figure  4. Relationships were 
identified between chemotherapy and solid tumor other than 
lung cancer, hematological cancer, and chronic steroid use, and 
between other immunocompromise and chronic steroid use.
Clinical and Microbiological Characteristics of Patients With 
Immunocompromise
Clinical features and disease severity of immunocompetent 
versus immunocompromised patients are shown in Table  1 
and Supplementary Table  3. Immunocompromised patients 
were significantly younger and malnourished, had a higher 
frequency of comorbid conditions, previous infections, and 
colonization by resistant pathogens, and had more frequent 
contacts with the healthcare system. The prevalences of severe 
pneumonia did not differ among the 2 study groups.
Microbiological testing was performed in 91.0% (596 of 
652) of immunocompromised and 86.0% (2626 of 3050) of 
immunocompetent patients (P  <  .001). Bacteremia was 
found in 6.0% (36 of 596) of immunocompromised and 5.5% 
(145 of 2626; P = .62) of immunocompetent patients. At least 
1 positive culture was obtained in 40.0% (238 of 596) immu-
nocompromised and 36.0% (935 of 2626) immunocompetent 
patients (P = .047). Microbiological findings are provided in 
Table 2 and Supplementary Table 4. Among pathogens cov-
ered by standard therapy, P. aeruginosa was more prevalent 
in immunocompromised patients (35 [5.9%] vs 98 [3.7%] 
patients; P < .02). Among pathogens not usually covered by 
standard therapy, immunocompromised patients were more 
likely to be infected by Nocardia spp. (4 [0.7%] vs 0 [0%] 
Figure 3. Prevalence of the number of risk factors present simultaneously in a single patient.
Figure 2. Prevalence of each single risk factor for immunocompromise.
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Figure 4. Network analysis between risk factors for immunocompromise.
Table 1. Clinical and Severity Characteristics of the 2 Study Groups (Immunocompetent vs Immunocompromised)
Variable
Patients, No. (%)a
P Value
Immunocompetent 
(n = 3050)
Immunocompromised
(n = 652)
Age, median (IQR) 69 (54–81) 65 (52–74) <.001
Underweight 125 (6.5) 41 (10.5) .004
Malnutrition 243 (8.0) 80 (12.3) <.001
Bedridden 355 (11.6) 60 (9.2) .04
Chronic aspiration 224 (7.3) 33 (5.1) .02
Bronchiectasis 136 (4.5) 42 (6.4) .03
Severe COPD 72 (2.4) 28 (4.3) .006
Interstitial lung disease 60 (2.0) 35 (5.4) <.001
Lung transplantation 0 (0.0) 7 (1.1) <.001
Tracheostomy 37 (1.2) 16 (2.5) .02
Hypertension 1401 (45.9) 254 (39.0) .001
Liver disease 103 (3.4) 37 (5.7) .005
Cirrhosis 50 (1.6) 20 (3.1) .02
Dementia 372 (12.2) 36 (5.5) <.001
Enteral tube feeding 36 (1.2) 16 (2.5) .01
Chronic renal failure 315 (10.3) 85 (13.0) .04
Hemodialysis 34 (1.1) 18 (2.8) .001
ICS use 462 (15.2) 128 (19.6) .005
PPI use 777 (25.5) 251 (38.5) <.001
Indwelling catheter 52 (1.7) 27 (4.1) <.001
Prior mycobacteria diseases 70 (2.3) 26 (4.0) .01
Prior ESBL 39 (1.3) 16 (2.5) .02
Prior Pseudomonas 68 (2.2) 33 (5.1) <.001
Severe CAP 840 (27.5) 190 (29.1) .41
Abbreviations: CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; ESBL, extended-spectrum β-lactamase; ICS, inhaled corticosteroids; IQR, interquartile 
range; PPI, proton pump inhibitors. 
aData represent No. (%) unless otherwise specified.
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patients; P < .001), nontuberculous mycobacteria (NTM) (5 
[0.8%] vs 2 [0.1%]; P <  .002), A.  fumigatus (8 [1.3%] vs 10 
[0.4%]; P < .01), P. jirovecii (12 [2.0%] vs 5 [0.2%]; P < .02), 
and viruses, such as coronavirus (3 [0.5%] vs 3 [0.1%]; 
P  <  .047), and respiratory syncytial virus (6 [1.0%] vs 7 
[0.3%]; P < .03).
Table 3. Multivariable Logistic Regression Analysis
Variable
OR (CI 95%) 
Pseudomonas  
aeruginosa Non-CAP Bacteria Fungi 
Mycobacterium  
tuberculosis 
Virus Other Than 
Influenza 
Severe COPD 2.89 (1.34–6.22) … … … …
Tracheostomy 6.95 (2.87–16.85) 2.91 (1.01–8.38) … … …
ICS use 1.76 (1.09–2.82) … … … …
Indwelling catheter 2.49 (1.02–6.06) … … … …
Prior Pseudomonas 19.20 (11.71–31.50) … … … …
COPD … 1.78 (1.07–2.99) … … …
Severe CAP … 2.36 (1.42–3.93) … … 2.56  (1.27–5.19)
AIDS … … 15.10 (6.36–35.88) … …
Hematological cancer … … 4.65 (1.85–11.69) … 5.49 (2.20–13.70)
Malnutrition … … … 5.14 (2.21–11.93) …
Blank cells indicate no statistical significancy.
Abbreviations: CAP community-acquired pneumonia; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; OR, odds ratio.
Table 2. Pathogens in the 2 Study Groups
Pathogen
Patients, No. (%)
P Value
Immunocompetent 
(n = 2626)
Immunocompromised 
(n = 596)
Pathogens covered by CAP therapy
 Streptococcus pneumoniae 218 (8.3) 50 (8.4) >.99
 Atypical 50 (1.9) 13 (2.2) .78
 Legionella 21 (0.8) 10 (1.7) .08
 MRSA 83 (3.2) 12 (2.0) .17
 MSSA 73 (2.8) 20 (3.4) .53
 Pseudomonas aeruginosa 98 (3.7) 35 (5.9) .02
 Haemophilus influenzae 65 (2.5) 10 (1.7) .31
 Klebsiella pneumoniae 89 (3.4) 22 (3.7) .81
 Influenza virus 126 (4.8) 28 (4.7) >.99
Pathogens not covered by CAP therapy
 Non-CAP bacteria
  Acinetobacter baumanii 33 (1.3) 7 (1.2) >.99
  Nocardia spp. 0 (0.0) 4 (0.7) <.001
 Mycobacteria
  Mycobacterium tuberculosis 21 (0.8) 5 (0.8) >.99
  NTM 2 (0.1) 5 (0.8) .002
 Fungi
 Aspergillus fumigatus 10 (0.4) 8 (1.3) .01
 Actinomyces 2 (0.1) 0 (0.0) >.99
 Cryptococcus 3 (0.1) 0 (0.0) .94
 Pneumocystis jirovecii 5 (0.2) 13 (2.2) <.001
Viruses
 Adenovirus 5 (0.2) 0 (0.0) .62
 Coronavirus 3 (0.1) 3 (0.5) .047
 Metapneumovirus 3 (0.1) 2 (0.3) .51
 RSV 7 (0.3) 6 (1.0) .03
MDR pathogens 231 (8.8) 54 (9.0) .54
Abbreviations: CAP, community-acquired pneumonia; MDR multidrug-resistant; MRSA methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus; NTM, nontuber-
culous mycobacteria; RSV, respiratory syncitial virus. 
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Once adjusted for confounders, no risk factors of immuno-
compromise have been recognized for P. aeruginosa infection. 
Likewise, pathogens not covered by usual CAP therapy were 
found to be associated not with immunocompromise but with 
chronic obstructive pulmonary disease (odds ratio [OR], 1.78; 
95% confidence interval [CI], 1.07–2.99; P = .03), tracheostomy 
(2.91; 1.01–8.38; P = .048), and severe pneumonia (2.36; 1.42–
3.93; P = .001) (Table 3).
Results showed that AIDS (OR, 15.10; 95% CI, 6.36–35.88; 
P ≤ .001) and hematological cancer (4.65; 91.85–11.69; P = .001) 
were independently associated with fungal infections; hemato-
logical cancer (5.49; 2.20–13.70; P < .001) and severe pneumo-
nia (2.56; 1.27–5.19; P =  .009) with infection by viruses other 
than influenza; and AIDS (4.41; 1.53–12.73; P = .006) and mal-
nutrition (4.50; 2.08–9.72; P < .001) with mycobacterial infec-
tions. An additional analysis was conducted on mycobacteria, 
including M. tuberculosis and NTM. At multivariable analysis, 
M.  tuberculosis was independently associated with malnutri-
tion only (OR, 5.14; 95% CI, 2.21–11.93; P < .001). At univar-
iate analysis, patients with AIDS were at higher risk for NTM 
(23.06; 4.39–121.12; P < .001).
A subanalysis was conducted among patients with chronic 
steroid use versus other risk factors for immunocompro-
mise. Patients with chronic steroid use seemed to be more 
frequently affected by bacteria not covered by standard 
CAP therapy (10 [3.4%] vs 1 [0.3%] patients; P  =  .002), 
Nocardia spp. in particular (4 [0.4%] vs 0 [0.0%]; P =  .03). 
No differences in the severity of the disease were found (see 
Supplementary Table 5).
DISCUSSION
The main findings of the present study are as follows: (1) 17.6% 
of patients admitted with pneumonia from the community have 
≥1 risk factor for immunocompromise, with significant differ-
ences among continents and countries (ranging from 15.4% to 
24.8% by continent and from 80.0% to 4.1% by country); (2) 
chronic steroid use is by far the most prevalent risk factor lead-
ing to immunocompromise, followed by hematological cancer 
and chemotherapy; (3) 1 of 2 immunocompromised patients 
has an overlap of ≥2 risk factors, which are also associated 
between one another in different ways; and (4) the 2 risk factors 
for immunocompromise independently associated with specific 
pathogens are AIDS (ie, fungal and mycobacterial infections) 
and hematological cancer (ie, fungal infection and viral infec-
tions other than influenza).
Almost 1 in 5 hospitalized patients with CAP are not immu-
nocompetent. Therefore, it is mandatory to provide clinicians 
with recommendations or guidelines for the management 
of hospitalized patients with pneumonia coming from the 
community who have risk factors for immunocompromise. 
Currently, there are no guidelines for assessing pneumonia in 
immunocompromised patients coming from the community. 
Randomized controlled trials (RCTs) and observational pro-
spective studies are missing owing to the fact that, generally, 
studies assessing management strategies for pneumonia exclude 
immunocompromised patients or take into account only a sin-
gle specific risk factor [12–21]. This lack of information about 
immunocompromise could lead to both underestimation of the 
real prevalence with a higher rate of treatment failure and to 
overestimation and overuse of wide-spectrum antibiotics.
We found a 17.6% global prevalence of immunocompromise 
among patients coming from the community with pneumo-
nia, with a significantly higher frequency in South and North 
America. This variability among continents and countries is 
probably attributable to different healthcare systems and rates 
of hospitalization of immunocompromised patients. Our anal-
ysis showed that the most frequent risk factor for immuno-
compromise is the chronic use of systemic steroids. Aging of 
the population and therapeutic advancements have favored the 
increased burden of chronic diseases and long-term therapies 
with immunosuppressive agents [8, 9]. In particular, steroids 
are the agents most frequently prescribed, for their wide spec-
trum of efficacy in several diseases [13, 17, 19]. Therefore, many 
patients presenting to the emergency room with pneumonia are 
receiving chronic steroid treatment. No data are available on 
this population group, and further studies are needed to char-
acterize these patients and provide individualized management. 
Hematological cancer and chemotherapy were other leading 
immunocompromised factors. These findings are consistent 
with those in previous studies; patients recruited in observa-
tional studies include patients with solid or hematological can-
cer and those who underwent chemotherapy with associated 
neutropenia [15–20, 22]. Dedicated guidelines and recommen-
dations are available, especially on respiratory viruses, fungi, 
and P. jirovecii [23–26].
Our network analysis showed that several risk factors for 
immunocompromise show associations, especially chemother-
apy, associated with hematological cancer and solid tumor, and 
other immunocompromise, associated with chronic steroid use. 
Moreover, neutropenic patients are well represented and mainly 
affected also by hematological cancer or under treatment with 
chemotherapy. Our results suggest that patients may have >1 risk 
factor characteristic and clinical assessment should be compre-
hensive, taking into consideration risk factors for immunocom-
promise and their associated biological mechanisms. In contrast, 
AIDS, lung transplantation, asplenia, and aplastic anemia seem 
to be less frequent at admission and to represent distinct clini-
cal entities. Findings of previous studies seem to be in line with 
our results, with AIDS patients considered as a distinct patient 
population and with very few observational studies available on 
asplenia and aplastic anemia [21, 27–31]
In agreement with previous reports, S.  pneumoniae is the 
leading microorganism in both immunocompromised and 
immunocompetent groups [32, 33]. Among pathogens covered 
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by standard CAP therapy, only P.  aeruginosa was more fre-
quently isolated in immunocompromised compared with 
immunocompetent patients. These findings differ from micro-
biological results of previous studies. Gram-positive bacteria, 
especially S. aureus, were more frequently identified in patients 
with immunocompromise of different causes [22, 30, 34]. Only 
Li and coauthors [13] found patients with immunological dis-
orders, treated with systemic steroids and cytotoxic agents, to 
have a higher incidence of infections caused by gram-negative 
bacteria, mainly P. aeruginosa. This similarity with our findings 
could be explained by the prevalence of patients exposed to 
chronic steroids in our cohort.
Among pathogens not covered by standard CAP therapy, 
immunocompromised patients were more frequently infected 
by Nocardia spp., NTM, P.  jirovecii, A.  fumigatus, and viruses 
other than influenza. Infections by P. jirovecii and NTM are fre-
quently identified in patients with AIDS [35]. P. jirovecii is also 
frequent in other types of immunocompromise, such as solid 
or hematological cancer in patients who underwent chemo-
therapy [18, 19, 36]. Fungal infections (eg, Candida spp. and 
A.  fumigatus) are highly incident in neutropenic hematologi-
cal cancer patients [22, 37]. Viral infections other than influ-
enza, especially respiratory syncytial virus, are more frequent 
in patients who underwent hematopoietic stem cell or lung 
transplantation [38, 39]. Conversely, Nocardia spp. infections 
are mainly described in solid organ transplant recipients [40]. 
These results, consistent with previous findings, suggest the 
need for a more in-depth microbiological workup, including 
community-acquired pathogens and microorganisms not cov-
ered by standard therapy.
Surprisingly, we found that risk factors for immunocom-
promise were not independently associated with P. aeruginosa 
or non–community-acquired bacteria; in contrast, AIDS and 
hematological cancer are both associated with fungal, myco-
bacterial, and noninfluenza viral pneumonia, respectively. 
Empirical therapy should include P. aeruginosa coverage, which 
is highly prevalent in immunocompromised patients. On the 
contrary, particular attention should be given to fungal, myco-
bacterial, and viral causes should be for patients admitted with 
AIDS and hematological cancer [21–29]. 
Finally, bacteremia rates did not differ between study groups. 
To our knowledge, there are no studies on bacteremia and 
immunocompromise in general. The majority of studies have 
focused on bacteremia in hematopoietic stem cell transplan-
tation, with prevalences varying from 6% to 44% depending 
on the type of bacteria and host-related factors [41–43]. Few 
studies addressed this topic in kidney transplant recipients, 
reporting a prevalence of bacteremia ranging from 25% to 69% 
[44, 45]. Finally, few studies have addressed HIV and bacte-
remia, with prevalences ranging from 10% to 25%, depend-
ing on the pathogen and grade of immunosuppression [46, 
47]. The prevalence of bacteremia in our study was 5T–6% in 
both immunocompetent and immunocompromised patients. 
Differences in the prevalence of bacteremia are due mainly to 
differences between the risk factors for immunocompromise in 
our study (chronic steroid use, hematological cancer, and che-
motherapy) and those previously reported in the literature.
The current study has both limitations and strengths. First of 
all, to our knowledge, this is the first study showing a worldwide 
perspective on immunocompromise among patients coming 
from the community with pneumonia, with a large and diverse 
sample of patients enrolled across different countries in 6 con-
tinents. However, we were not able to involve many investiga-
tors from Asia and Africa, and most cases occurred in North 
America and Europe, thus limiting the generalizability of our 
findings. Another major limitation is the unfeasibility of grad-
ing the severity of immunocompromise and, therefore, strati-
fying patients and defining the physiopathological interaction 
between different risk factors, especially with regard to the use 
of biological drugs and chronic steroids. Furthermore, poten-
tially important risk factors for an immunocompromised state, 
such as solid organ transplants other than lung, have not been 
specifically investigated. Finally, no outcome data have been 
collected, and this strongly limits our speculations as to the cor-
rect empiric antibiotic therapy for use in immunocompromised 
patients with CAP.
In conclusion, our study offers to the scientific community 
a perspective on immunocompromised patients coming from 
the community with pneumonia. Future prospective studies 
on patients with specific risk factors for immunocompromise 
could provide practical recommendations. In particular, it will 
be crucial to prepare guidelines on certain prevalent population 
groups, such as patients exposed to chronic steroids and those 
with hematological cancer.
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